Last Update 29 Apr 26

CCLD: Capital Discipline And AI Adoption Will Drive Future Repricing Confidence

Analysts have adjusted their price target on CareCloud to $6.31, citing concerns that acquisitive activity and plans for an aircraft purchase may be obscuring underlying revenue softness and creating questions around capital allocation discipline.

Analyst Commentary

Analyst commentary around CareCloud centers on how acquisitions and capital allocation choices, including the planned aircraft purchase, may influence the company’s ability to deliver consistent execution and support the current valuation.

Bullish Takeaways

Bullish analysts point to the recent Q4 report as "fair," which they view as a sign that core operations are still functioning, even as the business integrates multiple acquisitions.
Acquisitions are seen by some as a way to add scale and potential revenue streams. If integrated cleanly, these acquisitions could support long term growth expectations embedded in current price targets.
The updated price target of $6.31 signals that some analysts still see room for value creation if management can align spending and capital allocation with clearer revenue momentum.
Management’s willingness to invest in client engagement, including the planned aircraft for visiting current and prospective clients, is viewed by some as an attempt to support sales efforts and protect existing relationships.

Bearish Takeaways

Bearish analysts highlight that acquisitions appear to be masking underlying revenue declines, raising concerns about the quality and durability of the reported top line.
The heavy acquisitive activity in 2025 introduces integration risk, which could weigh on execution and make it harder to assess the true earnings power that should support the stock’s valuation.
The plan to acquire an aircraft, even framed as a client engagement tool, is viewed as a questionable capital allocation choice that "does not help" investor confidence around cost discipline.
With at least one firm maintaining a Neutral stance and a lower price target of $3.25, there is a visible gap between cautious and more optimistic targets. This gap signals uncertainty around both growth visibility and the balance between investment and profitability.

What's in the News

CareCloud elected to redeem all 1,511,372 outstanding shares of its Series B Preferred Stock at a cash redemption price of US$25.25 per share, plus US$2.27 per share in accrued and unpaid dividends, for a total of US$27.52 per share effective May 15, 2026. After this date, dividends on these shares will stop and holder rights will be limited to receiving the cash payment (Preferred Stock Buybacks).
The company filed a US$60 million follow on equity offering for its common stock structured as an at the market program, signaling an intent to access additional equity capital (Follow on Equity Offerings).
CareCloud issued earnings guidance for the fiscal year ending December 31, 2026. The company expects revenue between US$128 million and US$132 million and GAAP net income per share of US$0.20 to US$0.23 (Corporate Guidance: New/Confirmed).
Arkansas Otolaryngology Center selected CareCloud’s AI powered practice management and revenue cycle management solutions, including intelligent claims processing and AI driven financial analytics, to support operations and patient experience across its locations in Arkansas (Client Announcements).
Memorial Hospital in Marysville, Ohio signed on for CareCloud’s HealthLine supply chain management platform, adding an AI supported supply chain system aimed at improving visibility, charge capture, and inventory control across clinical operations (Client Announcements).

Valuation Changes

Fair Value: $6.31 is unchanged, indicating no adjustment to the modeled fair value per share in this update.
Discount Rate: The discount rate has fallen slightly from 8.43% to 8.33%, a modest shift that slightly reduces the rate used to discount future cash flows.
Revenue Growth: Revenue growth assumptions have fallen meaningfully from 9.88% to 8.46%, signaling a more cautious view on future top line expansion.
Net Profit Margin: Profit margin expectations have risen significantly from 7.31% to 13.21%, implying a higher assumed level of earnings efficiency relative to revenue.
Future P/E: The future P/E multiple has fallen sharply from 30.47x to 16.98x, pointing to a lower valuation multiple being applied to projected earnings.

8 views

Key Takeaways

Rapid AI-driven automation and new cloud-based solutions are streamlining workflows, driving efficiency, and unlocking access to untapped healthcare segments.
Expanding digital adoption, successful new product launches, and strategic acquisitions are boosting recurring revenues, market reach, and client retention.
Larger tech competitors, regulatory pressures, and rising costs threaten CareCloud's growth, margins, and market position, while expansion into new segments remains uncertain and risky.

Catalysts

About CareCloud

A healthcare information technology (IT) company, provides technology-enabled business solutions, Software-as-a-Service offerings, and related business services to healthcare providers and hospitals primarily in the United States.What are the underlying business or industry changes driving this perspective?

Recent deployment and rapid scaling of AI-driven automation (including cirrusAI Notes and cirrusAI Voice) is streamlining CareCloud's clinical and administrative workflows, reducing manual labor, and enhancing efficiency-positioning the company to expand EBITDA margins and operational leverage in coming quarters.
Full ONC HIT certification for a new, cloud-based, AI-enabled EHR for critical access hospitals opens up access to a largely untapped $1.5 billion rural hospital market segment, which is under pressure to modernize-potentially unlocking a new, durable revenue stream and supporting top-line growth.
Ongoing digital adoption in healthcare and industry momentum behind cloud migration, AI, and automation are driving strong client interest in CareCloud's next-generation intelligent platform, with growing customer adoption rates (notably >75% conversion from trial to paid for cirrusAI Notes), which will likely improve recurring revenues and subscription growth.
Accretive tuck-in acquisitions, enabled by strong free cash flow and an undrawn credit facility, are expanding CareCloud's addressable market, cross-selling opportunities, and average revenue per user, supporting both short-term earnings and long-term revenue growth through broader platform adoption.
Advances in patient engagement tools and upcoming launches such as an AI-powered front desk agent and personal health record platform position CareCloud to benefit from rising demand for connected, interoperable, remote care solutions-driving both incremental revenue and improved client retention in a consolidating healthcare IT market.

CareCloud Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming CareCloud's revenue will grow by 8.5% annually over the next 3 years.
Analysts assume that profit margins will increase from 3.2% today to 13.2% in 3 years time.
Analysts expect earnings to reach $20.3 million (and earnings per share of $0.46) by about April 2029, up from $3.9 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $26.3 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 17.0x on those 2029 earnings, down from 34.7x today. This future PE is lower than the current PE for the US Healthcare Services industry at 31.5x.
Analysts expect the number of shares outstanding to grow by 0.41% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.33%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Increasing adoption of AI-driven EHR and revenue cycle management platforms by much larger tech competitors could overshadow CareCloud, resulting in market share erosion and limiting long-term revenue growth.
The company's expansion into the underserved critical access hospital segment and specialty EHR markets is in early stages, with uncertain client uptake and the risk that entrenched legacy providers could impede CareCloud's ability to drive significant new revenue streams.
Substantial investments in AI talent and product development may raise operating costs faster than incremental revenue or margin gains, especially if customer adoption of AI-centric products is slower than anticipated, putting pressure on net margins.
Growing consolidation among payers and providers could shift pricing power and contract terms away from smaller vendors like CareCloud, jeopardizing its ability to maintain or grow revenue and exerting downward pressure on earnings.
Tightening data privacy regulations and evolving interoperability mandates could increase compliance and R&D costs for CareCloud disproportionately compared to larger competitors, limiting its ability to sustain competitive differentiation and potentially compressing margins over time.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $6.31 for CareCloud based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $8.0, and the most bearish reporting a price target of just $3.25.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $153.7 million, earnings will come to $20.3 million, and it would be trading on a PE ratio of 17.0x, assuming you use a discount rate of 8.3%.
Given the current share price of $3.18, the analyst price target of $6.31 is 49.6% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on CareCloud?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Cloud EHR And AI Automation Will Unlock New Opportunities